Recently Featured

Exegenesis Bio and Modalis Sign Research Deal for Duchenne Therapy

September 28, 2026
Exegenesis Bio and Modalis Therapeutics have entered into a research partnership and license agreement to advance MDL-201, a promising therapeutic candidate targeting Duchenne muscular dystrophy (DMD). This collaboration marks a significant step forward in the development of innovative treatments for a condition that currently has limited therapeutic options. The partnership is poised to leverage the…

Angelo de Claro Outlines Regulatory Agenda as New FDA Oncology Chief

September 28, 2026
In his inaugural interview as the new head of the FDA’s Oncology Center of Excellence (OCE), Dr. Angelo de Claro emphasized his commitment to advancing the legacy of innovation within the center. He articulated a regulatory agenda that not only aims to enhance organizational strength but also to pursue ongoing modernization of regulatory processes. This…

PD-L2 Blockade May Reduce Harmful Aging Cell Buildup

September 28, 2026
A recent study from Cedars-Sinai Health Sciences University reveals that programmed cell death ligand 2 (PD-L2), a protein involved in immune checkpoint signaling, may play a crucial role in the accumulation of senescent cells—damaged cells that contribute to age-related dysfunction. Published in Cell Metabolism, the research indicates that PD-L2 allows these harmful cells to evade…

Ongoing Cases